Kirr Marbach & Co. LLC IN Acquires New Position in Orthofix Medical Inc. (NASDAQ:OFIX)

Kirr Marbach & Co. LLC IN acquired a new stake in Orthofix Medical Inc. (NASDAQ:OFIX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 30,462 shares of the medical device company’s stock, valued at approximately $532,000. Kirr Marbach & Co. LLC IN owned 0.08% of Orthofix Medical as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Franklin Resources Inc. lifted its stake in shares of Orthofix Medical by 37.4% in the third quarter. Franklin Resources Inc. now owns 20,960 shares of the medical device company’s stock valued at $337,000 after purchasing an additional 5,702 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Orthofix Medical by 14.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 324,807 shares of the medical device company’s stock valued at $5,073,000 after acquiring an additional 39,901 shares in the last quarter. Barclays PLC increased its holdings in Orthofix Medical by 38.8% during the 3rd quarter. Barclays PLC now owns 122,472 shares of the medical device company’s stock valued at $1,912,000 after acquiring an additional 34,210 shares in the last quarter. HighTower Advisors LLC increased its holdings in Orthofix Medical by 114.9% during the 3rd quarter. HighTower Advisors LLC now owns 89,183 shares of the medical device company’s stock valued at $1,393,000 after acquiring an additional 47,680 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Orthofix Medical by 1.4% during the 3rd quarter. Geode Capital Management LLC now owns 839,189 shares of the medical device company’s stock valued at $13,111,000 after acquiring an additional 11,559 shares in the last quarter. Institutional investors and hedge funds own 89.76% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Stifel Nicolaus upgraded shares of Orthofix Medical from a “hold” rating to a “buy” rating and raised their target price for the company from $18.00 to $24.00 in a report on Friday, November 8th. Roth Mkm restated a “buy” rating and set a $22.00 target price (up from $20.00) on shares of Orthofix Medical in a report on Friday, November 8th. Finally, Canaccord Genuity Group began coverage on shares of Orthofix Medical in a report on Wednesday, January 22nd. They set a “buy” rating and a $24.00 price target for the company. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $23.33.

Orthofix Medical Stock Up 1.2 %

Shares of NASDAQ OFIX opened at $18.59 on Wednesday. The company has a 50-day simple moving average of $18.08 and a 200-day simple moving average of $17.03. The company has a current ratio of 2.39, a quick ratio of 1.11 and a debt-to-equity ratio of 0.25. Orthofix Medical Inc. has a 12 month low of $12.08 and a 12 month high of $20.73.

Orthofix Medical (NASDAQ:OFIX) last released its earnings results on Thursday, November 7th. The medical device company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.57). Orthofix Medical had a negative return on equity of 21.25% and a negative net margin of 15.18%. The company had revenue of $196.61 million during the quarter, compared to analyst estimates of $196.60 million. During the same period in the prior year, the business posted ($0.77) earnings per share. Sell-side analysts anticipate that Orthofix Medical Inc. will post -2.81 earnings per share for the current year.

Insider Buying and Selling

In other Orthofix Medical news, CEO Massimo Calafiore sold 9,203 shares of Orthofix Medical stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $17.14, for a total transaction of $157,739.42. Following the transaction, the chief executive officer now directly owns 124,151 shares of the company’s stock, valued at $2,127,948.14. The trade was a 6.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Julie Andrews sold 4,655 shares of Orthofix Medical stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $17.89, for a total transaction of $83,277.95. Following the transaction, the chief financial officer now directly owns 28,312 shares in the company, valued at approximately $506,501.68. This trade represents a 14.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,675 shares of company stock valued at $423,238. Insiders own 2.60% of the company’s stock.

Orthofix Medical Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.